ArticleChest2025
Beryllium Lymphocyte Proliferation Test: Differential Diagnosis of Sarcoidosis and Chronic Beryllium Disease.
Article in Chest, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Systemic chronic beryllium disease: beyond lung disease.Occupational and environmental medicine · 2026Article
- Additional diagnostic potential of transbronchial lung cryobiopsy in bronchoscopic assessment of sarcoidosis and chronic beryllium disease: a retrospective analysis of 321 patients.BMJ open respiratory research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic beryllium disease (CBD) is considered a phenocopy of sarcoidosis, generally caused by occupational exposure to beryllium. Its diagnosis relies on the demonstration of beryllium sensitization by the beryllium lymphocyte proliferation test (BeLPT). RESEARCH QUESTION: How well does the BeLPT discriminate between CBD and sarcoidosis in patients with suspected beryllium exposure and what are the clinical characteristics of these 2 groups? STUDY DESIGN AND
methodsBeLPT results and clinical characteristics of patients with suspected beryllium exposure were retrospectively analyzed.
resultsA total of 1,234 BeLPTs from 431 patients were included. Of 210 patients with established granulomatous disease, 87 patients (41.4%) were diagnosed with CBD and 106 (50.5%) were diagnosed with sarcoidosis; in 17 cases (8.1%), the BeLPT results were inconclusive. The remaining 221 patients had other diagnoses or could not be classified. A single BeLPT had a sensitivity of 61.5% (95% CI, 55.8-67.0) and a specificity of 90.8% (95% CI, 86.5-93.9). For split-sample tests, the sensitivity and specificity were 76.0% (95% CI, 67.7-82.8) and 80.4% (95% CI, 71.4-87.1), respectively. Patients with CBD had lower lung function than those with sarcoidosis, as measured by FVC (mean z score, -1.58 vs -0.75, respectively; P = .002). A restrictive pattern was more common in CBD than in sarcoidosis (41.0% vs 14.8%, respectively; OR, 3.99; P = .002).
interpretationDespite low sensitivity, the BeLPT was able to detect CBD in 41.4% of patients with a granulomatous disease and suspected beryllium exposure. CBD was associated with lower lung function compared with sarcoidosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.